<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737422</url>
  </required_header>
  <id_info>
    <org_study_id>6781</org_study_id>
    <nct_id>NCT03737422</nct_id>
  </id_info>
  <brief_title>The Effects of Hesperidin and Flaxseed in Prediabetes</brief_title>
  <official_title>Evaluation of the Effects of Hesperidin and Flaxseed Supplementation in Patients With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of Hesperidin and flaxseed supplement in patients with prediabetes, 50
      patients will be randomly allocated to control group or 2 capsules Hesperidin and 30 gram
      flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and
      exercise program too. At the first and the end of the intervention, lipid profiles, blood
      pressure, blood sugar, inflammatory and anthropometric factors will be assessed and compared
      between groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prediabetes</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of participants with normal plasma glucose</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>hesperidin and flaxseed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>hesperidin and flaxseed</intervention_name>
    <description>2 capsuls hesperidin and 30 g flaxseed</description>
    <arm_group_label>hesperidin and flaxseed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>no supplementation</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 70 years prediabetes: impaired fasting glucose (&gt;100 mg/dL) and/or HbA1C
             5.7% to 6.5%, and overweight or obese with body mass index range of 25 to 40 kg/m2

        Exclusion Criteria:

          -  pregnancy or lactation

          -  A history of Cardiovascular disease, Pulmonary disease, Renal disease &amp; Celiac
             disease; Cirrhosis

          -  Following program to lose weight in recent 3 mo
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

